Literature DB >> 19184153

Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Chengguo Zuo1, Feng Wen, Jiaqing Li, Yan Liu, Meng Li.   

Abstract

To investigate the changes in the multifocal electroretinography (ERG) after combined intravitreal bevacizumab and photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV) patients. Thirteen eyes of 13 patients were included in the study. The latencies and average response densities of all the six ring retinal regions were measured and compared before treatment and 1, 3, and 6 months after treatment. The latencies of the N1 and P1 waves in all the six rings remained unchanged compared with pre-treatment. Significant increase of average response densities of both P1 in ring 1 (P = 0.023) and N1, P1 in ring 2 (P = 0.028 and 0.046, respectively) were detected at 3 months post-treatment. The increase of P1 amplitude densities in ring 1 (P = 0.015) and N1, P1 amplitude densities in ring 2 (P = 0.031 and 0.034, respectively) were also significant at 6 months post-treatment. In conclusion, combined intravitreal bevacizumab and PDT is associated with an increase of multifocal ERG centrally in PCV patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184153     DOI: 10.1007/s10633-009-9166-9

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  37 in total

1.  The changes of multifocal electroretinography in the early stage of photodynamic therapy for choroidal neovascularization.

Authors:  Libin Jiang; Chenjin Jin; Feng Wen; Shizhou Huang; Dezheng Wu; Lezheng Wu
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

2.  Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.

Authors:  M Mauget-Faÿsse; M Quaranta-El Maftouhi; E De La Marnièrre; A Leys
Journal:  Eur J Ophthalmol       Date:  2006 Sep-Oct       Impact factor: 2.597

3.  Long-term follow-up of polypoidal choroidal vasculopathy after photodynamic therapy with verteporfin.

Authors:  Kaori Sayanagi; Fumi Gomi; Miki Sawa; Masahito Ohji; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-04-17       Impact factor: 3.117

4.  Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Yumiko Kurashige; Atsushi Otani; Manabu Sasahara; Yuko Yodoi; Hiroshi Tamura; Akitaka Tsujikawa; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2008-07-09       Impact factor: 5.258

5.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

6.  Idiopathic polypoidal choroidal vasculopathy (IPCV).

Authors:  L A Yannuzzi; J Sorenson; R F Spaide; B Lipson
Journal:  Retina       Date:  1990       Impact factor: 4.256

7.  Polypoidal choroidal vasculopathy in Caucasians.

Authors:  B A Lafaut; A M Leys; B Snyers; F Rasquin; J J De Laey
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2000-09       Impact factor: 3.117

8.  Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up.

Authors:  Wai-Man Chan; David T L Liu; Timothy Y Y Lai; Haitao Li; Jian-Ping Tong; Dennis S C Lam
Journal:  Clin Exp Ophthalmol       Date:  2005-12       Impact factor: 4.207

9.  Localized retinal electrophysiological and fundus autofluorescence imaging abnormalities in maternal inherited diabetes and deafness.

Authors:  Caren Bellmann; Magella M Neveu; Hendrik P N Scholl; Chris R Hogg; Pamela P Rath; Sharon Jenkins; Alan C Bird; Graham E Holder
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-07       Impact factor: 4.799

10.  Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

View more
  3 in total

1.  Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.

Authors:  Akitaka Tsujikawa; Sotaro Ooto; Kenji Yamashiro; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

2.  Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab.

Authors:  Kohei Ishikawa; Hiroaki Nishihara; Shinsuke Ozawa; Chang-Hua Piao; Yasuki Ito; Mineo Kondo; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-31       Impact factor: 3.117

Review 3.  Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases.

Authors:  In Hwan Hong; Sung Pyo Park
Journal:  Indian J Ophthalmol       Date:  2017-07       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.